GlaxoSmithKline
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
A Safety, Tolerability, Pharmacokinetics (PK) and Target Engagement (TE) Study of GSK3858279 in Healthy Participants and Evaluation of the Efficacy of Repeat Doses in Participants With Osteoarthritis (OA)
Phase 1
Completed
- Conditions
- Pain, Inflammatory
- Interventions
- Drug: GSK3858279 IVDrug: Placebo matching to GSK3858279 (SC or IV)Drug: GSK3858279 SCDrug: Placebo matching to GSK3858279 (SC)
- First Posted Date
- 2018-04-02
- Last Posted Date
- 2024-03-22
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 97
- Registration Number
- NCT03485365
- Locations
- 🇬🇧
GSK Investigational Site, Manchester, United Kingdom
A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC /VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Phase 4
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: budesonide/formoterolDrug: albuterol/salbutamolDrug: Placebo to match budesonide/formoterolDrug: Placebo to match FF/UMEC/VIDrug: placebo to match tiotropiumDevice: ELLIPTADevice: MDIDevice: HandiHaler
- First Posted Date
- 2018-03-27
- Last Posted Date
- 2020-10-28
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 732
- Registration Number
- NCT03478696
- Locations
- 🇩🇪
GSK Investigational Site, Leipzig, Germany
A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Phase 4
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: budesonide/formoterolDrug: albuterol/salbutamolDrug: Placebo to match budesonide/formoterolDrug: Placebo to match FF/UMEC/VIDrug: placebo to match tiotropiumDevice: ELLIPTADevice: MDIDevice: HandiHaler
- First Posted Date
- 2018-03-27
- Last Posted Date
- 2020-10-28
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 729
- Registration Number
- NCT03478683
- Locations
- 🇳🇱
GSK Investigational Site, Zutphen, Netherlands
Oral and Dermal Tolerability Clinical Study of an Experimental Denture Wipe
Not Applicable
Completed
- Conditions
- Denture Cleansers
- Interventions
- Other: Tap WaterDevice: Experimental Denture Wipe
- First Posted Date
- 2018-03-27
- Last Posted Date
- 2018-10-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 152
- Registration Number
- NCT03478644
- Locations
- 🇺🇸
GSK Investigational Site, Fort Wayne, Indiana, United States
An Open-label Study to Evaluate Correct Use and Ease of Use of the ELLIPTA DPI in Pediatric Subjects With Asthma
Phase 4
Completed
- Conditions
- Asthma
- Interventions
- Drug: Placebo DPIDevice: ELLIPTA DPIOther: Ease of use questionnaires
- First Posted Date
- 2018-03-27
- Last Posted Date
- 2021-03-26
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 222
- Registration Number
- NCT03478657
- Locations
- 🇨🇦
GSK Investigational Site, Windsor, Ontario, Canada
A Comparative Study Between Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy Versus Tiotropium Monotherapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Phase 4
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: Albuterol/salbutamolDrug: Placebo to match tiotropiumDrug: Placebo to match FF/UMEC/VIDevice: ELLIPTA inhalerDevice: HANDIHALERDevice: MDI
- First Posted Date
- 2018-03-22
- Last Posted Date
- 2021-07-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 800
- Registration Number
- NCT03474081
- Locations
- 🇷🇺
GSK Investigational Site, Voronezh, Russian Federation
INTREPID: Investigation of TRELEGY Effectiveness: Usual Practice Design
Phase 4
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- First Posted Date
- 2018-03-16
- Last Posted Date
- 2020-09-07
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 3109
- Registration Number
- NCT03467425
- Locations
- 🇬🇧
GSK Investigational Site, Warrington, United Kingdom
Use of Diagnostic Measures in Chronic Obstructive Pulmonary Disease (COPD) in Routine Practice and Their Impact on Treatment Decisions
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Other: Doctor's questionnaireOther: Subject file
- First Posted Date
- 2018-03-14
- Last Posted Date
- 2019-01-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 251
- Registration Number
- NCT03465332
- Locations
- 🇩🇪
GSK Investigational Site, Berlin, Germany
The Safety of Boostrix Following Routine Immunization of Pregnant Women
Completed
- Conditions
- Whooping Cough
- Interventions
- Other: Safety assessment following routine immunization with Boostrix
- First Posted Date
- 2018-03-13
- Last Posted Date
- 2022-05-18
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 65783
- Registration Number
- NCT03463577
- Locations
- 🇺🇸
GSK Investigational Site, Pasadena, California, United States
Anemia Studies in CKD: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat- Iron (ASCEND: Fe)
Phase 2
Completed
- Conditions
- Anaemia
- Interventions
- Drug: rhEPODrug: Ferrous sulfate containing the stable iron isotope (57Fe)Drug: Ferrous sulfate containing the stable iron isotope (58Fe)
- First Posted Date
- 2018-03-07
- Last Posted Date
- 2024-03-27
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 15
- Registration Number
- NCT03457701
- Locations
- 🇺🇸
GSK Investigational Site, San Antonio, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath